Applications for the 2027 IPC Fellowship Program will be accepted from August 31 through September 30, 2026.
Clinical fellowship applicants must hold an MD degree or equivalent, and be within five years of completion of specialization OR in training to achieve such specialization (e.g. Fellow, Resident, Registrar, etc.).
Research fellowship applicants may hold either an MD or PhD degree and must be within five years of training completion.
All applicants should have a demonstrated interest in psoriasis.
Research Track Details:
Research fellows will be matched with clinical, translational, or laboratory-based psoriasis research mentors. Fellows are expected to observe and contribute to an active study or co-develop a small-scale research project with their mentor. The program emphasizes flexibility, relationship-building, and foundational research skill development as well as active interaction between research and clinical care to foster long-term collaborations. The on-site visit will last up to 12 weeks, and financial support will be $1,100 per week.
Clinical Track Details:
Clinical fellows will be matched with mentors primarily involved in clinical practice and patient care. Fellows are expected to observe and develop their patient treatment skills. The program emphasizes clinical practice learning and skill development as well as active interaction between clinical care and research. The on-site visit will be for a minimum of two weeks up to four weeks, and financial support will be $1,100 per week.
Both the Research and Clinical Fellowships include:
In-person and Virtual Mentoring
Congress attendance
Other
Awarded fellows receive a stipend to cover the following expenses:
For questions about the IPC International Fellowship Program, please send an email to Fellowship@psoriasiscouncil.org.
SPECIAL NOTE: If AI is used to assist in writing the Personal Statement, ensure it has been adequately reviewed before submission. In addition to covering the points above, it should reflect the applicant’s enthusiasm for developing their skills in psoriasis and reflect the applicant’s unique voice and perspective.
SPECIAL NOTE: Please do not submit a general letter of recommendation. Letters should be written by someone who knows the applicant personally and can specifically speak to their interest in psoriasis, as well as their suitability for this fellowship opportunity.
WORKING TOWARDS CONTINUAL PROGRAM IMPROVEMENT IN THE BEST INTERESTS OF THE PAST, PRESENT AND FUTURE IPC INTERNATIONAL FELLOWS
The IPC International Fellowship Program Advisory Committee is comprised of IPC Board Members, Councilors, and Junior Councilors who work to ensure that the further development of IPC’s Fellowship program is in keeping with and in support of IPC’s strategic plan in partnership with the executive team. Together they review, analyze, and generate new ideas to work towards continual program improvement in the best interests of the past, present and future IPC International Fellows.
A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.
In this article, IPC Board Member Lluís Puig, MD, PhD, gives his expert commentary on two randomized trials showing that ixekizumab plus tirzepatide outperforms ixekizumab alone for skin clearance, joint control, and weight loss in psoriasis and PsA.
IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.
Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.
IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.
In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.
